**(4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylate** is a chemical compound with a complex structure. Let's break down its components and potential significance:
**Structure:**
* **4-Ethyl-2-oxochromen-7-yl:** This part indicates a **chromone** derivative. Chromones are heterocyclic compounds containing a pyrone ring fused to a benzene ring. The 4-Ethyl indicates an ethyl group attached at the 4th position of the chromone ring, and 2-oxo signifies a carbonyl group (C=O) at the 2nd position.
* **Furan-2-carboxylate:** This part refers to a **furan** derivative. Furans are five-membered heterocyclic rings containing one oxygen atom. The 2-carboxylate signifies a carboxyl group (-COOH) attached at the 2nd position of the furan ring.
**Importance for Research:**
The specific importance of (4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylate depends on the research area. However, given its structure, this compound might be of interest for:
* **Medicinal Chemistry:** Chromones and furans are known for their diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. This compound could be explored for its potential therapeutic applications.
* **Organic Chemistry:** The compound might be used as a building block or intermediate in synthetic chemistry to create new and complex molecules with desired properties.
* **Materials Science:** Chromones and furans can exhibit interesting optical and electronic properties, potentially making this compound useful for developing new materials.
**Note:** The compound's specific properties and importance are likely tied to a specific research project or application. Without further context, it is impossible to definitively state why it is significant. To understand its importance, you would need to know the specific research question or application in which it is involved.
ID Source | ID |
---|---|
PubMed CID | 807412 |
CHEMBL ID | 1498450 |
CHEBI ID | 149820 |
Synonym |
---|
OPREA1_867697 |
OPREA1_497821 |
MLS001083053 , |
smr000664873 |
(4-ethyl-2-oxochromen-7-yl) furan-2-carboxylate |
CHEBI:149820 |
HMS2965L12 |
AKOS016357741 |
CHEMBL1498450 |
STL458531 |
4-ethyl-2-oxo-2h-chromen-7-yl furan-2-carboxylate |
cid_807412 |
2-furancarboxylic acid (4-ethyl-2-oxo-1-benzopyran-7-yl) ester |
furan-2-carboxylic acid (4-ethyl-2-keto-chromen-7-yl) ester |
(4-ethyl-2-oxidanylidene-chromen-7-yl) furan-2-carboxylate |
bdbm47916 |
432006-53-6 |
sr-01000242089 |
SR-01000242089-1 |
eim07-13523 |
Role | Description |
---|---|
anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
coumarins | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acid sphingomyelinase | Homo sapiens (human) | Potency | 12.5893 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
glucocerebrosidase | Homo sapiens (human) | Potency | 7.0795 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 17.4208 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 17.4208 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 35.4813 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 25.9290 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
geminin | Homo sapiens (human) | Potency | 5.8048 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
3C-like protease, partial | Infectious bronchitis virus | IC50 (µMol) | 2.9620 | 1.0850 | 5.6067 | 9.8110 | AID1890 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |